Drs. Frick and Arnold receive “Bradley Catalyst” grant funding

The UWM Research Foundation has awarded “Bradley Catalyst” funding to Prof. Frick to evaluate new lead compound EGX854, which has demonstrated greater selectivity and 4-fold better potency. EGX854 has also shown potential for better brain penetration. Dr. Frick will evaluate this new lead compound in rodent models of hot flashes, memory, anxiety, and depressive behaviors. Dr. Frick is the CSO of Estrigenix, a UWM/Marquette/Concordia startup company.

Bradley Catalyst” funding was also awarded to Prof. Arnold to identify lead compounds that can reduce high levels of thymic stromal lymphopoietin (TSLP) found in atopic dermatitis (AD) patients. TSLP expressed in the skin has been identified as key cytokine to trigger AD and is involved in the atopic march leading to allergic rhinitis and asthma. Reduction of TSLP during childhood AD might prevent subsequent atopic disorders and would enable to prevent chronic disease. Dr. Arnold is the CSO of Pantherics, a UWM startup company.